Federal Register of Legislation - Australian Government

Primary content

PB 3 of 2011 Arrangements as made
This Arrangement amends the National Health (Chemotherapy Pharmecuticals Access Program) Special Arrangement 2010 (PB No. 117 of 2010)to make minor amendments to the listings of various chemotherapy pharmaceutical benefits that may be supplied under the Special Arrangement.
Administered by: Health
Registered 31 Jan 2011
Tabling HistoryDate
Tabled HR08-Feb-2011
Tabled Senate08-Feb-2011
Date of repeal 01 Dec 2011
Repealed by National Health (Chemotherapy Pharmaceuticals Access Program) Special Arrangement 2011 (No. PB 87 of 2011)

 

PB 3 of 2011

National Health (Chemotherapy Pharmaceuticals Access Program) Special Arrangement Amendment Instrument 2011 (No. 1)

 

National Health Act 1953

___________________________________________________________________________

 

I, FELICITY MCNEILL, Acting First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.

Dated  26   January 2011

 

 

 

 

 

 

 

 

 

 

 

FELICITY MCNEILL

Acting First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health and Ageing

___________________________________________________________________

 

 

 

 

 

1              Name of Amendment Instrument

 

(1)                This Instrument is the National Health (Chemotherapy Pharmaceuticals Access Program) Special Arrangement Amendment Instrument 2011 (No.1).

 

(2)                This Instrument may also be cited as PB 3 of 2011.

 

2                Commencement

                            This Instrument commences on 1 February 2011.

3              Amendments to PB 117 of 2010

                            Schedule 1 amends PB 117 of 2010.

 


Schedule 1                   Amendments

[1]   Schedule 1, entries for Doxorubicin – Pegylated Liposomal

 omit from the column headed ‘Responsible Person’ (twice occurring):

         SH

and insert (twice occurring):

         JC

[2]   Schedule 1, entry for Ondansetron in the form Tablet 4 mg (as hydrochloride dihydrate)

insert in the columns in the order indicated, after “APO-Ondansetron”:

 

 

 

Ondansetron-DRLA

RZ

EMP

C3050

 

4

0

 

[3]   Schedule 1, entry for Ondansetron in the form Tablet 8 mg (as hydrochloride dihydrate)

insert in the columns in the order indicated, after “APO-Ondansetron”:

 

 

 

Ondansetron-DRLA

RZ

EMP

C3050

 

4

0

 

[4]   Schedule 2, entry for Code “PL”

omit from the column headed ‘Responsible person’:

            Virgo Unit Trust

and insert:

            The Trustee for Virgo Unit Trust (trading as Phebra)

 

 

Note

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. 

See http://www.frli.gov.au.